| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
64,628,000 |
| Market
Cap: |
8.85(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$69.96 - $159.4 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ascendis Pharma is a biopharmaceutical company. Co.'s primary investigational product candidate, TransCon Growth Hormone, is in development as a once-weekly prodrug of recombinant human growth hormone as a potential treatment for pediatric growth hormone deficiency. Co. is also using its TransCon technologies to develop other product candidates to address rare endocrine diseases. These product candidates include TransCon Parathyroid Hormone as a potential treatment for adult hypoparathyroidism and TransCon C-Type Natriuretic Peptide as a potential therapeutic option for achondroplasia, the most common form of dwarfism.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
6.25 (4.37%) 
